Alamar Biosciences (ALMR) Stock Price, News & Analysis

Company Overview

Alamar Biosciences is a life sciences tools company that develops technologies for measuring proteins in biological samples. Its products are designed to help researchers study disease biology and support the development of tools for earlier disease detection and precision medicine.

The company’s offerings include its NULISA platform, which enables sensitive measurement of multiple proteins, and the ARGO HT system, an automated instrument for running assays. Its applications include research into neurodegenerative diseases, cancer and inflammation.

Founded in 2018 and headquartered in Fremont, California, Alamar serves researchers and other organizations working in life sciences and biomedical research.

Key Stats

• Today's Range: $29.21 to $31.94
• 50-Day Range: $23.52 to $38.13
• 52-Week Range: $18.84 to $39.61
• Volume: 667,712 shs
• Average Volume: 745,923 shs
• Market Capitalization: $2.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

Alamar Biosciences Stock Analysis - MarketRank™

Alamar Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 623rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alamar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Alamar Biosciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Alamar Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alamar Biosciences are expected to grow in the coming year, from ($1.29) to ($1.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alamar Biosciences is -14.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alamar Biosciences is -14.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alamar Biosciences has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.23% of the float of Alamar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Alamar Biosciences has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alamar Biosciences has recently decreased by 16.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alamar Biosciences does not currently pay a dividend.

Dividend Growth

Alamar Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.90

News Sentiment

Alamar Biosciences has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Alamar Biosciences this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for ALMR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alamar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alamar Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,503,514.00 in company stock.

Percentage Held by Institutions

Alamar Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/15/2026
• Citi Annual Global Healthcare Conference 2026: 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ALMR
• CIK: 2104204
• Web: alamarbio.com
• Phone: (510) 626-9888
• Fax: 510-605-5062
• Employees: 222
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Alamar Biosciences: $33.00
• High Price Target: $36.00
• Low Price Target: $27.00
• Potential Upside/Downside: +7.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.82 million
• Net Margins: -48.22%
• Pretax Margin: -47.62%
• Return on Equity: -78.71%
• Return on Assets: -20.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.49
• Quick Ratio: 7.87

Sales & Book Value

• Annual Sales: $74.21 million
• Price / Sales: 28.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.37 per share
• Price / Book: 7.05

Miscellaneous

• Outstanding Shares: 69,480,000
• Free Float: N/A
• Market Cap: $2.14 billion
• Optionable: N/A
• Beta: N/A